inclusion criteria: * requires hospitalization for covid-19 infection * has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry * requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less * has radiographic evidence of pulmonary infiltrates * females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. * men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. * adequate hematologic, hepatic and renal function as described in the protocol * must be within 10 days of confirmed diagnosis of covid-19

inclusion criteria: * requires hospitalization for covid-19 infection * has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry * requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less * has radiographic evidence of pulmonary infiltrates * females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. * men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. * adequate hematologic, hepatic and renal function as described in the protocol * must be within 10 days of confirmed diagnosis of covid-19

inclusion criteria: requires hospitalization for covid-19 infection has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less has radiographic evidence of pulmonary infiltrates females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. adequate hematologic, hepatic and renal function as described in the protocol must be within 10 days of confirmed diagnosis of covid-19

inclusion criteria: requires hospitalization for covid-19 infection has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less has radiographic evidence of pulmonary infiltrates females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. adequate hematologic, hepatic and renal function as described in the protocol must be within 10 days of confirmed diagnosis of covid-19

inclusion criteria: - requires hospitalization for covid-19 infection. - has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry. - requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less.. - has radiographic evidence of pulmonary infiltrates. - females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. - men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. - adequate hematologic, hepatic and renal function as described in the protocol. - must be within 10 days of confirmed diagnosis of covid-19.

inclusion criteria: - requires hospitalization for covid-19 infection. - has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by reverse transcription polymerase chain reaction (rt-pcr) test before study entry. - requires supplemental oxygen for pulmonary distress related to covid-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less.. - has radiographic evidence of pulmonary infiltrates. - females of childbearing potential (fcbp) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. fcbp must be referred to a qualified provider of contraceptive methods if needed. fcbp must have a negative serum pregnancy test as of screening. - men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a fcbp. - adequate hematologic, hepatic and renal function as described in the protocol. - must be within 10 days of confirmed diagnosis of covid-19.